Address
121 South Orange Avenue
Orlando, FL 32801
United States of America (the)
Phone
407 377 6695
Website
Sector
Healthcare
Industry
Biotechnology
Employees
13
First IPO Date
October 01, 2021
| Name | Title | Pay | Year Born |
| Gareth Sheridan | Founder, Chief Executive Officer & Director | 542,107 | 1990 |
| Michael Myer | President of Pocono Pharmaceutical | 40,600 | 1984 |
| Gerald Goodman | Chief Financial Officer & Chief Accounting Officer | 147,671 | 1948 |
| Alan Smith | Chief Operating Officer & President of 4P Therapeutics | 161,673 | 1966 |
| Serguei Melnik | Founder, President, Company Secretary & Executive Chairman | 542,107 | 1974 |
| Tyler Overk | Head of Active Intelligence | 0 | 1984 |
| Jeffrey Patrick | Chief Scientific Officer | 0 | 1970 |
Nutriband Inc. specializes in developing a diverse range of pharmaceutical products delivered via transdermal patches. The company's most advanced program centers on AVERSA fentanyl, an innovative fentanyl transdermal system engineered to prevent abuse. This extended-release patch provides healthcare professionals and patients with a continuous opioid therapy solution for the ongoing management of chronic pain. Its development pipeline also includes other treatments, such as AVERSA buprenorphine and AVERSA methylphenidate. Additionally, Nutriband is working on exenatide for individuals with type 2 diabetes and follicle stimulating hormone as a treatment for infertility. The company also holds a licensing agreement with Rambam Med-Tech Ltd. to further the development of RAMBAM Closed System Transfer Devices. Nutriband Inc. was founded in 2016 and its main offices are located in Orlando, Florida.